vTv Therapeutics, a biotech developing treatments for Alzheimer's disease and type 2 diabetes, raised $117 million by offering 7.8 million shares at $15, the low end of the range of $15 to $17. vTv Therapeutics plans to list on the Nasdaq under the symbol VTVT. vTv Therapeutics initially filed confidentially on 5/14/2015. Piper Jaffray and Stifel acted as lead managers on the deal.
